Growth opportunities August Bioservices has pursued significant expansion in Nashville with over $150 million invested and hundreds of new roles since 2020, signaling a growth trajectory and potential for increased contract manufacturing capacity and longer-term partnerships.

Aseptic expertise Specialization in sterile injectable fill-finish for vials, syringes, and flexible IV bags positions August as a prime partner for brands needing robust aseptic manufacturing capabilities and scalable CDMO services.

Financing momentum Recent $65 million Series B financing and a track record of multi-year investments indicate strong financial backing, which can support on-ramps for new product programs and expanded capacity with favorable terms.

Leadership recognition CEO Jenn Adams was named Healthcare Technology CEO of the Year, highlighting strong leadership and strategic vision that can reassure clients about execution risk and collaborative value delivery on complex programs.

Market positioning Revenue in the mid-range and a strategy centered on end-to-end development to commercial production, combined with state-of-the-art facilities post-renovation, create a compelling value proposition for biotech and pharma sponsors seeking a reliable sterile CDMO partner.